RESUMO
OBJECTIVE: To explore the relationship between the quantities of HBV and the models of serologic markers. METHODS: Real-time fluorescent quantitative PCR was used to measure the HBV DNA and ELISA was used to detect the antigen/antibody of HBV. RESULTS: The patients whose HBV copies were more than 10(3)/ml accounted for 87.3%, whose copies were more than 10(7)/ml accounted for 66.7% among the HBsAg and HBeAg -positive patients. The patients whose HBV copies were less than 10(3)/ml accounted for 74.5%, whose HBV copies were more than 10(7)/ml accounted for 8.3% among the HBeAg-negative patients. The HBV copies of HBeAg-positive patients were significantly more than HBeAg-negative patients (P<0.01). The HBV copies of anti-HBe-negative patients were significantly more than anti-HBe-positive patients (P<0.01). The HBV DNA was detected in some HBsAg-negative patients. One patient's HBV copies were as high as 1.59 10(9)/ml. CONCLUSIONS: The HBV copies of HBeAg-positive patients are significantly more than HBeAg-negative patients, The HBV copies of anti-HBe-negative patients are significantly more than the anti-HBe-positive patients. However, some HBeAg-positive patient's HBV copies are very low, and some HBeAg-negative patient's HBV copies are very high. HBV DNA even could be detected in some HBsAg-negative patients. It is difficult to judge accurately the quantities of HBV and infectivity according to the serologic markers for a specific patient.
